Table 2.
The number of individuals in different cohorts who gave a positive response to immunodominant regions within the N protein
| SARS-CoV-2 variant | Number of individuals who gave a positive antibody response | ||||
|---|---|---|---|---|---|
| P5/6 | P23/24 | P40/41 | P53/54 | At least for one pair | |
| WT (n = 12) | 10 (83.3%) | 12 (100%) | 11 (91.7%) | 8 (66.7%) | 12/12 (100%) |
| Delta (n = 12) | 11 (91.7%) | 9 (75%) | 11 (91.7%) | 10 (83.3%) | 12/12 (100%) |
| Omicron+ vaccinated (n = 22) | 20 (90.9%) | 16 (72.7%) | 20 (90.9%) | 18 (81.8%) | 20/22 (90.9%) |
| Sinopharm (n = 12) | 12 (100%) | 11 (91.7%) | 11 (91.7%) | 11 (91.7%) | 12/12 (100%) |
| Total (n = 58) | 53 (91.4%) | 48 (82.8%) | 53 (91.4%) | 47 (81.0%) | 56/58 (96.5%) |
| Number of individuals who gave a positive antibody response | |||||
| AstraZeneca (n = 10) | 0 | 1 (10%) | 1 (10%) | 0 | 1/10 (10%) |
| Sputnik V (n = 10) | 0 | 0 | 1 (10%) | 0 | 1/10 (10%) |
| Moderna (n = 10) | 1 (10%) | 1 (10%) | 0 | 0 | 2/10 (20%) |
| Total (n = 30) | 1 (3.3%) | 2 (6.7%) | 2 (6.7%) | 0 | 4/30 (13.3%) |